Therapeutic Strategy of Extracorporeal Carbon Dioxide Removal in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Combined With Central Airway Stricture: A Case Report Authors: Jingjing Deng, Yinjie Ye, Ming Zhang, Lunjie Lu Published: 2026 ABSTRACT ABSTRACTThis case report highlights a novel and successful therapeutic strategy for a patient with acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and severe central airway stricture (CAS). We demonstrate the use of extracorporeal CO2 removal (ECCO2R) as a critical physiological bridge, stabilizing the patient's hypercapnic respiratory failure and allowing for the safe and definitive management of the airway stenosis through bronchoscopic stenting.Keywords: central airway strictures (CAS), chronic obstructive pulmonary disease (COPD), extracorporeal carbon dioxide removal (ECCO2R) Introduction Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with a prevalence of about 530 million cases in 2024, causing a significant economic burden [1, 2]. Among them, there are 100 million patients in China alone, with an annual mortality rate of approximately 1 million, the highest in the world, highlighting an urgent need to reduce the prevalence of COPD [3]. The pathophysiology of COPD is characterized by incompletely reversible airflow limitation [4], leading to inadequate ventilation and persistent inflammation of the small airways. This results in airway obstruction, which impairs the expulsion of carbon dioxide (CO2) and leads to retention. In severe cases, CO2 clearance can be achieved through a high‐flow nasal cannula (HFNC), non‐invasive ventilator (NIV), invasive mechanical ventilation (IMV) or tracheotomy, if necessary [5, 6]. Extracorporeal carbon dioxide removal (ECCO2R) is an extracorporeal life‐support technique that removes CO2 retention from the body using an extracorporeal membrane lung (‘artificial lung’) [7, 8]. In China, continuous renal replacement therapy (CRRT) combined with ECCO2R is increasingly used as part of a multi‐organ support platform for acute respiratory distress syndrome (ARDS) combined with refractory hypercapnia, particularly during the coronavirus disease‐2019 epidemic [9]. ECCO2R can be effectively used for patients experiencing acute exacerbation of COPD (AECOPD) due to its high CO2 removal efficiency. This technique can help in (1) avoiding IMV caused by HFNC or NIV failure and (2) promoting the early withdrawal of IMV patients [10, 11, 12]. It has been reported that COPD may be associated with benign central airway stricture (CAS) [13]. Airflow restriction during the expiratory phase of the central airway can lead to varying degrees of dyspnea, and it can be severe enough to cause death by asphyxiation [14]. Currently, bronchoscopic interventions are the most common treatment options and offer significant benefits to patient [15]. In the present case, the patient has COPD, with CO2 retention impairing consciousness and complicating the condition with CAS. This condition is rare in clinical diagnosis and treatment. Case Report A 70‐year‐old man with a long history of emphysema, coronary artery disease, and diabetes—without any history of stroke or smoking—had the middle lobe of his right lung resected 2 years ago due to carcinoma in situ, resulting in the loss of segments B4 and B5 right. Over the past year, he had been hospitalized several times for AECOPD and CO2 retention; however, he did not experience any consciousness disorders. On this occasion, he was admitted to a rural hospital for several days. During treatment, he developed impaired consciousness, which gradually worsened, prompting his transfer to the emergency room (ER) of our hospital, where he was intubated and admitted to the intensive care unit (ICU). The patient's arterial partial pressure of CO2 (PaCO2) was 56.6 mmHg upon admission to the ER; however, CO2 levels gradually increased during ICU ventilator‐assisted ventilation, reaching a peak of 80.4 mmHg within 48 h. Simultaneously, abnormalities in the ventilator parameters were observed, including an elevated airway resistance (R aw), pressure limitation, and low minute ventilation, which did not match the patient's condition. Consequently, a bedside bronchoscopy was performed, revealing significant stenosis of the main trachea and right main bronchus. After discussing the patient's condition with the family, our team decided to proceed with ECCO2R to improve respiratory acidosis and reduce PaCO2 levels. To address the CAS, Professor Bai Chong of Shanghai Changhai Hospital was invited to perform ‘endoscopic main bronchial stenting’ for a limited schedule. The flow chart of the consultation time for this patient is illustrated in Figure 1. Flow chart of the timeline of important events during patient visits. Table 1 illustrates the daily CO2 flow removed by ECCO2R in this patient, ranging from 98 to 217 mL, whereas the range of extracorporeal membrane oxygenation (ECMO) blood flow (ECBF) was between 1.34 and 1.91 L, indicating a favourable efficiency. Figure 2 presents a comparison of pH and CO2 partial pressure in the premembrane, postmembrane and right radial arteries during ECCO2R application. The blood gas analysis results taken every 4 h for 1 day before ECCO2R withdrawal revealed a pH range of 7.35–7.37 and PaCO2 levels of 54.9–55.6 mmHg. The efficient removal of CO2 alleviated COPD symptoms, providing permissive airway conditions and sufficient time for endoscopic bronchial stent implantation. The patient was successfully taken off the ventilator on August 21st. Figures 3 and 4 illustrate the chest computed tomography (CT) and endoscopic airway changes before and after stent implantation, respectively. Bronchoscopy identified 50% tracheal stenosis and 80% right main bronchus stenosis. Following temporary stenting, both main bronchi showed marked improvement, with luminal diameter restored to approximately 80% of normal, accompanied by a sudden drop in R aw and a rise in minute ventilation. At 6‐month follow‐up, the patient ambulates and performs daily activities despite residual dyspnea, without re‐intervention or COPD hospitalization. Chest CT confirms a well‐positioned stent and patent airway. TABLE 1CO2 removal flow under ECCO2R.DatePCO2ML (exp)SGFECBF (L)VCO2ML24.07.2024315.01.5021725.07.20243103.01.9112626.07.2024353.51.3417227.07.2024284.01.7915728.07.2024145.01.829829.07.2024314.01.5117430.07.2024184.01.7710131.07.2024204.01.84112 Note: PCO2ML (exp), carbon dioxide partial pressure at the membrane lung gas exit port; ECBF, extracorporeal membrane oxygenation blood flow; SGF, swept gas flow (L/min); VCO2ML = PCO2ML (exp) * SGF/713 * 1000. CO2 removal flow under ECCO2R. Note: PCO2ML (exp), carbon dioxide partial pressure at the membrane lung gas exit port; ECBF, extracorporeal membrane oxygenation blood flow; SGF, swept gas flow (L/min); VCO2ML = PCO2ML (exp) * SGF/713 * 1000. pH and CO2 partial pressure in the premembrane, postmembrane, and right radial arteries during ECCO2R application. Abbreviation: RA, radial artery. Changes in chest CT (red arrow for right main bronchus, green arrow for left main bronchus): (a) Admission to ER CT; (b) status of temporary stent implantation in each of the right and left main bronchi; (c) Y‐stent implantation status. Bronchoscopy: (a) Tracheal stenosis; (b) right main bronchial stenosis; (c) left main bronchial stenosis several days after temporary stenting of the right main bronchus; (d) Y‐silicone bronchial stent implantation status; (e) airway stent record card (including type of stent, size, placement and others). Discussion COPD is characterized by small airway obstruction, whereas CAS involves large airway stricture. For this patient, these two conditions were exacerbating factors that led to severe hypoxemia and hypercapnia, which triggered impaired consciousness and life‐threatening complications. ECCO2R effectively removes CO2 from the body, alleviating respiratory failure, reducing respiratory power consumption, and decreasing dynamic lung hyperinflation [16]. Compared with the ECMO technique, which mainly focuses on improving oxygenation and requires a blood flow of > 2500 mL/min, ECCO2R requires a blood flow of only 200–2000 mL/min. This is due to the linear dissociation curve of CO2 in blood and its significantly higher solubility in blood compared to oxygen (approximately 200:1) [17, 18]. This patient underwent conventional venovenous‐ECCO2R with the placement of a 24Fr Crescent double‐lumen internal jugular vein catheter for blood drainage and return. The procedure began with a gradual increase in speed to approximately 3000 rpm and a blood flow rate of 1.5 L/min, with monitoring of vital signs and blood gas analysis. In the study by Burki et al. (11 cases) [19], the use of a 15.5F double‐lumen catheter resulted in significant CO2 removal at a relatively lower blood flow rate (300–500 mL/min); however, extubation was achieved in only three cases. More recently, relevant high‐quality randomized controlled trials (RCTs) such as REST [20] and VENT‐AVOID [21] investigated venovenous‐ECCO2R, with blood flow of up to 550 mL/min. Contrarily, our produced is based on a medium flow rate (0.5–2.5 L/min) and has been used in our medical centre. Several clinical cases have used a flow rate of 1.5–2.5 L/min, which is not only effective in CO2 removal but also has a longer application time. Additionally, some studies included patients with a pH of 7.24–7.26 [19, 22, 23], with one study reporting a pre‐enrollment pH of 7.29–7.32 [21]. Our patient presented with less acidemia upon admission to the ER, exhibiting a pH of 7.31, which gradually declined as the disease progressed. Before initiating ECCO2R, the pH ranged from 7.22 to 7.25, whereas the post‐treatment pH range increased to 7.35–7.50, reflecting thebetter efficiency of CO2 clearance with medium flow rates in patients with severe acidemia, highlighting a significant improvement in acidemia. A previous ECCO2R study indicated that bleeding is a common adverse event associated with the intervention [20, 24]. Notably, this patient was monitored for complication; no major bleeding, thrombocytopenia or device‐related thrombosis occurred. Heparin was managed with a target activated coagulation time (ACT) of 160–200 s, which was achieved, and no bleeding events were noted. The activated partial thromboplastin time (APTT) target of 50–60 s was also maintained. We have also observed different conclusions regarding the timing and duration of the ECCO2R application. Some studies do not support early application in patients with AECOPD with a high risk of noninvasive ventilation (NIV) failure [21, 23]. However, others recommend early application of ECCO2R for successful withdrawal of patients with AECOPD from IMV, despite the variable duration of intubation (26 h–13 days) [19, 25]. Additionally, the latest VENT‐AVOID study revealed that using ECCO2R to avoid intubation or facilitate extubation did not significantly improve ventilator‐free days by day 5. This patient was successfully evacuated from ECCO2R after 7 days of application, achieving ventilator‐free days by Day 30. Although this aligns with the RCT study described above, this patient had an obstruction in both large and small airways, indicating that these conclusions may not be applicable to other cases. Furthermore, patients with hypoxemic respiratory failure with lower lung compliance and higher alveolar dead space in AECOPD were selected to respond better to ECCO2R [26, 27]. In this case, the patient exhibited an abnormally elevated R aw, auto‐positive end‐expiratory pressure (PEEPi), and decreased lung compliance, leading to severe hypoxemia and hypercapnia, in which the significant impact of large airway obstruction cannot be ignored. CAS is airway stricture of the trachea, right and left main bronchi and right middle bronchus. In our patient, the lower part of the trachea and the right and left main bronchi had different degrees of stenosis. Compared to malignant airway strictures, benign airway stenosis is more challenging to manage, has a longer survival period, and is associated with a higher likelihood of long‐term complications [28]. Managing benign central airway stenosis presents unique challenges in the field of interventional pulmonology. Historically, surgery was the main treatment option for benign airway stenosis; however, transbronchoscopic intervention has now become the standard approach. The application of ECCO2R was crucial in alleviating COPD, correcting consciousness and acidosis, and serving as a bridge to definitive bronchoscopic management of severe CAS. This year, our medical center has implemented ECCO2R in three patients with AECOPD. The results demonstrated a high CO2 clearance rate, achieving early extubation and withdrawal, including one case with 12‐h extubation after IMV and no COPD exacerbation over the following 6 months. However, ECCO2R is not routinely used to treat patients with AECOPD, highlighting an urgent need for more high‐quality RCTs to confirm its efficacy and safety in preventing endotracheal intubation and assisting early extubation. With this goal in mind, our medical center is participating in the ECCO2R multicenter clinical trial program and looks forward to additional data and evidence to support its use. Funding This study was supported by the Key Clinical Specialties of Jiangsu Province; Yixing People's Hospital Internal Research Project (No. YRY2026B004). Ethics Statement This study was approved by the Ethics Committee of Yixing people's hospital (No. 2024‐033‐01). Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images using the form provided by the Journal. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements The authors would like to express their gratitude to all those who contributed to this study, directly or indirectly. Deng J., Ye Y., Zhang M., and Lu L., “Therapeutic Strategy of Extracorporeal Carbon Dioxide Removal in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Combined With Central Airway Stricture: A Case Report,” Respirology Case Reports 14, no. 9 (2026): e70753, 10.1002/rcr2.70753. Associate Editor: Shunsuke Minagawa Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.